Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 3/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.44 |
| ▸ | PTGDR2 | Q9Y5Y4 | 12/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.38 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1369027 | 0.88 | PTGS1 (0.48) | PTGS1PTGS2PTGDR2CYP2C19ELANE | |
| SCHEMBL1367360 | 0.86 | PBRM1 (0.49) | PTGS1PTGS2PTGDR2ADRA2CMAOA | |
| SCHEMBL1367423 | 0.85 | PTGDR2 (0.44) | PTGS1PTGS2PTGDR2 | |
| SCHEMBL1369884 | 0.85 | PTGDR2 (0.53) | PTGS1PTGS2PTGDR2CYP1A2CYP3A4 | |
| SCHEMBL1367148 | 0.78 | ALDH1A1 (0.49) | PTGDR2HPGDMAPT | |
| SCHEMBL1369227 | 0.77 | PTGDR2 (0.47) | PTGDR2 | |
| SCHEMBL1370449 | 0.76 | PTGDR2 (0.68) | PTGDR2 | |
| SCHEMBL1367124 | 0.75 | L3MBTL1 (0.38) | PTGS1PTGS2 | |
| SCHEMBL1367408 | 0.75 | PTGDR2 (0.69) | PTGDR2 | |
| SCHEMBL1369878 | 0.74 | PTGDR2 (0.70) | PTGDR2MAOASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461329-B2 | Isoquinoline derivative | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2013-06-11 | — | — | US | disclosed |
| US-20110288293-A1 | ISOQUINOLINE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-11-24 | — | — | US | disclosed |
| EP-2377851-A1 | ISOQUINOLINE DERIVATIVE | Taisho Pharmaceutical Co., Ltd. (JP) | 2011-10-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288293-A1 | ISOQUINOLINE DERIVATIVE | HRH1, HRH2, HRH4 | PTGS1 40/4885PTGS2 28/4885PTGDR2 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.